<DOC>
	<DOCNO>NCT00433550</DOCNO>
	<brief_summary>This phase II trial study well give irinotecan hydrochloride together oxaliplatin capecitabine work first-line therapy treat patient metastatic unresectable locally advance small bowel cancer . Drugs use chemotherapy , irinotecan hydrochloride , oxaliplatin , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Irinotecan , Oxaliplatin , Capecitabine First-Line Therapy Treating Patients With Metastatic Unresectable Locally Advanced Small Bowel Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : To assess confirmed tumor response combination oxaliplatin , irinotecan ( irinotecan hydrochloride ) , capecitabine patient advance adenocarcinoma small bowel dose accord UGT1A1 genotype . SECONDARY OBJECTIVES : 1 . To assess toxicity regimen group patient . 2 . To gain preliminary data whether microsatellite instability influence outcome within arm . 3 . To gain preliminary data whether evidence celiac disease may affect toxicity outcome . 4 . To gain preliminary data whether site tumor origin ( duodenal , jejunal , ileal ) affect response survival . OUTLINE : Patients assign 1 3 treatment group base UGT1A1 genotype . GROUP 1 ( 6/6 UGT1A1 genotype ) : Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute oxaliplatin IV 2 hour day 1 capecitabine orally ( PO ) twice daily ( BID ) day 2-15 . GROUP 2 ( 6/7 UGT1A1 genotype ) : Patients receive irinotecan hydrochloride group 1 . They also receive oxaliplatin capecitabine group 1 low dos . GROUP 3 ( 7/7 UGT1A1 genotype ) : Patients receive irinotecan hydrochloride , oxaliplatin , capecitabine group 1 low dos . In group , treatment repeat every 3 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 week 2 year periodically thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion Criteria Confirmation UDP glucuronosyltransferase 1 family , polypeptide A complex locus ( UGT1A1 ) TA indel genotype 6/6 , 6/7 , 7/7 preregistration prior registration Patient willingness provide serum sample analysis celiac disease ( tissue transglutaminase antibody ) Small bowel adenocarcinoma , either metastatic locally advance surgically resectable ; NOTE : periampullary carcinoma appendiceal cancer eligible Histologic cytologic confirmation adenocarcinoma consistent small bowel origin ; biopsy primary tumor metastatic site primary small bowel tumor currently previously present Measurable disease ; patient lesion &gt; = 1 cm &lt; 2 cm , spiral compute tomography ( CT ) scan imaging must use tumor assessment Life expectancy &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 &gt; = 4 week since prior major surgery time registration &gt; = 2 week completion radiation treatment Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelets &gt; = 100,000/mm^3 Serum glutamic oxaloacetic transaminase ( SGOT ) = &lt; 5 x upper normal limit ( UNL ) ; = &lt; 2.5 x UNL liver metastasis Total bilirubin : For 6/6 patient : = &lt; upper limit normal ( ULN ) For 6/7 7/7 patient : = &lt; 2.0 x ULN Hemoglobin &gt; = 9.0 g/dL Creatinine = &lt; 1.5 x UNL ( &gt; 1.5 x UNL , calculate creatinine clearance check . ; &gt; 60 mL/min , patient eligible study ) Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Exclusion Criteria Prior chemotherapy regimen advance small bowel cancer ( prior adjuvant chemotherapy fluorouracil ( 5FU ) /leucovorin permit last dose administer &gt; = 3 month prior registration ) ; prior oxaliplatin irinotecan use adjuvant therapy permit Prior radiotherapy &gt; 25 % bone marrow Active uncontrolled infection Evidence serious intercurrent illness ( e.g. , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) Pregnant woman ; woman childbearing potential men must agree use adequate contraception ( diaphragm , birth control pill , injection , foam , intrauterine device [ IUD ] , abstinence , etc . ) duration study participation ; woman become pregnant suspect pregnant participate study , inform treat physician immediately study treatment discontinue Nursing woman ; breastfeed discontinue mother treated agent Men woman childbearing potential unwilling employ adequate contraception Current evidence malignancy besides small bowel adenocarcinoma , exception nonmelanoma skin cancer Known central nervous system metastases carcinomatous meningitis Preexisting sensory neuropathy &gt; = grade 2 cause interfere function Concurrent therapy sorivudine , brivudine , lamivudine , stavudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>